[Skip to Content]
[Skip to Content Landing]
Article
December 1987

Skin as the Site of Vitamin D Synthesis and Target Tissue for 1,25-Dihydroxyvitamin D3Use of Calcitriol (1,25-Dihydroxyvitamin D3) for Treatment of Psoriasis

Author Affiliations

From the US Department of Agriculture/Human Nutrition Research Center and Department of Physiology, Tufts University (Drs Holick and Smith), and Department of Dermatology, New England Medical Center (Dr Pincus), Boston. Dr Holick is now with Boston University Medical School.

Arch Dermatol. 1987;123(12):1677-1683a. doi:10.1001/archderm.1987.01660360108022
Abstract

• Vitamin D is a hormone, not a vitamin. The skin is responsible for producing vitamin D. During exposure to sunlight, ultraviolet radiation penetrates into the epidermis and photolyzes provitamin D3 to previtamin D3. Previtamin D3 can either isomerize to vitamin D3 or be photolyzed to lymisterol and tachysterol. Vitamin D is also sensitive to sunlight and is photolyzed to 5,6-transvitamin D3, suprasterol I, and suprasterol II. In Boston, solar irradiation only produces previtamin D3 in the skin between the months of March and October. Aging, sunscreens, and melanin all diminish the capacity of the skin to produce previtamin D3. Once formed, vitamin D3 enters the circulation and is sequentially metabolized to 25-hydroxyvitamin D3 and 1,25-dihydroxyvitamin D3 (1,25-[OH]2-D3). The epidermis possesses receptors for 1,25-(OH)2-D3.1,25-(OH)2-D3D3 inhibits the proliferation of cultured keratinocytes and induces them to terminally differentiate. The topical or oral administration of 1,25-(OH)2-D3 has proved to be effective for the treatment of psoriasis. Therefore, the skin is the site for the synthesis of vitamin D and a target tissue for its active metabolite. The successful use of 1,25-(OH)2-D3 for the treatment of psoriasis heralds a new approach for the treatment of this enigmatic disorder.

(Arch Dermatol 1987;123:1677-1683a)

×